Curevo
Curevo develops vaccines for varicella and herpes zoster, with a lead product candidate, amezosvatein, an adjuvanted subunit vaccine for the prevention of shingles in adults. The organization aims to improve patient experience and vaccination rates by offering a vaccine with non-inferior efficacy and improved reactogenicity compared to existing options.
Facts
- HQ
- Bothell, Washington, US
- Sectors
- Biotechnology Research
- Founded
- 2017
- Employees
- 30
- Stage
- Series B
- Members see funding amounts. .
Is this your organization? Claim it
Members see Curevo's funding rounds, amounts and investors.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events